They further showed that activation of STING signaling in tumor cells promoted an induction of the chemokines CCL2 and CCL7 that were associated with immune resistance and was able to be reversed via the incorporation of a CCR2 (CCL2 and CCL7 receptor) antagonist into the formulation. Here, STING1 is linked to neoplasm.